131 results on '"Sinkovits, György"'
Search Results
2. Open ADAMTS-13 conformation index predicts earlier relapse in immune-mediated thrombotic thrombocytopenic purpura
3. Class switch towards spike protein-specific IgG4 antibodies after SARS-CoV-2 mRNA vaccination depends on prior infection history
4. Evidence, detailed characterization and clinical context of complement activation in acute multisystem inflammatory syndrome in children
5. Circulating mortalin in blood and activation of the alternative complement pathway as risk indicators in COVID-19 infection
6. Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpura
7. Immunogenic hotspots in the spacer domain of ADAMTS13 in immune‐mediated thrombotic thrombocytopenic purpura
8. Open ADAMTS-13 conformation index predicts earlier relapse in immune-mediated thrombotic thrombocytopenic purpura
9. Anti-Inflammatory Cytokine Profiles in Thrombotic Thrombocytopenic Purpura—Differences Compared to COVID-19.
10. Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome
11. Open ADAMTS-13 conformation index predicts earlier relapse in immune-mediated thrombotic thrombocytopenic purpura
12. Von Willebrand Factor and Platelet Levels before Conditioning Chemotherapy Indicate Bone Marrow Regeneration following Autologous Hematopoietic Stem Cell Transplantation
13. Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome
14. Early Increase in Complement Terminal Pathway Activation Marker sC5b-9 Is Predictive for the Development of Thrombotic Microangiopathy after Stem Cell Transplantation
15. 96 Association between acute stage biomarker levels, severity and long-term outcome in COVID-19
16. Complement activation, inflammation and relative ADAMTS13 deficiency in secondary thrombotic microangiopathies
17. Complement lectin pathway activation is associated with COVID-19 disease severity, independent of MBL2 genotype subgroups
18. Hemolytic uremic syndrome in the setting of COVID-19 successfully treated with complement inhibition therapy: An instructive case report of a previously healthy toddler and review of literature
19. Hemolytic uremic syndrome in the setting of COVID-19 successfully treated with complement inhibition therapy: An instructive case report of a previously healthy toddler and review of literature
20. Distinction of early complement classical and lectin pathway activation via quantification of C1s/C1-INH and MASP-1/C1-INH complexes using novel ELISAs
21. Elevated plasma neutrophil elastase concentration is associated with disease activity in patients with thrombotic thrombocytopenic purpura
22. Complement Levels at Admission Reflecting Progression to Severe Acute Kidney Injury (AKI) in Coronavirus Disease 2019 (COVID-19): A Multicenter Prospective Cohort Study
23. Decreased circulating dipeptidyl peptidase-4 enzyme activity is prognostic for severe outcomes in COVID-19 inpatients
24. Associations between the von Willebrand Factor—ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality
25. Value of Prophylactic Plasma Treatment and Incidence of Acute Episodes in Patients Enrolled in the International Hereditary Thrombotic Thrombocytopenic Purpura Registry
26. Insight into the Natural History of Hereditary Thrombotic Thrombocytopenic Purpura: Short- and Long-Term Outcomes in a Longitudinally Followed Large Patient Cohort of the International Hereditary TTP Registry
27. Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura
28. A szerzett trombotikus trombocitopéniás purpura patogenezisében szerepet játszó genetikai és immunológiai tényezők vizsgálata
29. Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection
30. Soluble Dipeptidyl-Peptidase 4 (sDPP4) Serum Activity Is Associated With the Severity of COVID-19 Disease and is a Strong Prognostic Biomarker of Mortality
31. Validation of Early Increase in Complement Activation Marker sC5b-9 as a Predictive Biomarker for the Development of Thrombotic Microangiopathy After Stem Cell Transplantation
32. Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura
33. Elevated Systemic Pentraxin-3 Is Associated With Complement Consumption in the Acute Phase of Thrombotic Microangiopathies
34. Description of the First Cases with ADAMTS13 Mutations in Hungary
35. Open ADAMTS13 Conformation in Immune-Mediated Thrombotic Thrombocytopenic Purpura Is Induced By Anti-ADAMTS13 Autoantibodies and Corresponds with an Ongoing ADAMTS13 Pathology
36. Elevated pentraxin-3 is associated with alternative pathway dysregulation in the acute phase of thrombotic microangiopathies
37. Concentration and Subclass Distribution of Anti-ADAMTS13 IgG Autoantibodies in Different Stages of Acquired Idiopathic Thrombotic Thrombocytopenic Purpura
38. Role of complement in the pathogenesis of thrombotic microangiopathies
39. Platelet Count, ADAMTS13 Activity, von Willebrand Factor Level and Survival in Patients with Colorectal Cancer: 5-Year Follow-up Study
40. The role of human leukocyte antigen DRB1-DQB1 haplotypes in the susceptibility to acquired idiopathic thrombotic thrombocytopenic purpura
41. Decreased Neutrophil Extracellular Trap Degradation in Shiga Toxin-Associated Haemolytic Uraemic Syndrome
42. Endothelin-1 as an endothelial cell biomarker in atypical hemolytic uremic syndrome
43. Corrigendum to “Elevated plasma neutrophil elastase concentration is associated with disease activity in patients with thrombotic thrombocytopenic purpura” [Thromb. Res. 133 (2014) 616–621]
44. Carboxiterminal pro-endothelin-1 as an endothelial cell biomarker in thrombotic thrombocytopenic purpura
45. Caplacizumab Therapy in Immune Thrombotic Thrombocytopenic Purpura
46. Decreased Neutrophil Extracellular Trap Degradation in Shiga Toxin-Associated Haemolytic Uraemic Syndrome.
47. Carboxiterminal pro-endothelin-1 as an endothelial cell biomarker in thrombotic thrombocytopenic purpura
48. UPDATE ON THE ROLE OF THE COMPLEMENT SYSTEM IN THE PATHOGENESIS OF THROMBOTIC MICROANGIOPATHIES.
49. Description of the First Cases with ADAMTS13Mutations in Hungary
50. Complement lectin pathway activation is associated with COVID-19 disease severity, independent of MBL2 genotype subgroups.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.